Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-06

AUTHORS

C Even, U Lassen, J Merchan, C Le Tourneau, J-C Soria, C Ferte, F Ricci, J T Diener, E Yuen, C Smith, G J Oakley, K A Benhadji, Christophe Massard

ABSTRACT

Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients with adenoid cystic carcinoma (ACC) who received the dose-escalation-recommended phase 2 dose (RP2D), established previously (Massard C, et al., Annals Oncol 2018, 29:1911-17). Methods Patients with advanced or metastatic cancer, measurable disease, ECOG-PS ≤1, and baseline tumor tissue were enrolled. Primary objectives were to identify a safe RP2D, confirm this dose in expansion cohorts, and document anti-tumor activity. Secondary objectives included safety and progression-free survival (PFS). The ACC expansion cohort received the RP2D regimen of 50 mg crenigacestat thrice per week in a 28-day cycle until disease progression or other discontinuation criteria were met. Results Twenty-two patients with ACC were enrolled in the expansion cohort (median age of 60 years). Median treatment duration was 3 cycles with 6 patients remaining on treatment. There were no objective responses; 1 (5%) patient had an unconfirmed partial response. Disease control rate was 73% and 4 patients had stable disease ≥6 months. Median PFS was 5.3 months (95%CI: 2.4-NE)) for the 22 patients; and 7.7 months (95%CI: 4.0-NR) and 2.4 months (95%CI: 1.1-NE) in the subgroup of patients in second-line (n = 7) or ≥ third-line (n = 9), respectively. Frequent treatment-related-adverse events (all grades) included diarrhea, fatigue, vomiting, decreased appetite, dry mouth, and dry skin. There were no new safety signals. Conclusion The crenigacestat RP2D regimen induced manageable toxicity and limited clinical activity, without confirmed responses, in heavily pretreated patients with ACC. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-019-00739-x

DOI

http://dx.doi.org/10.1007/s10637-019-00739-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113261863

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30953269


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Drug Development Department (DITEP), Institut Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800, Villejuif Cedex, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Even", 
        "givenName": "C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rigshospitalet", 
          "id": "https://www.grid.ac/institutes/grid.475435.4", 
          "name": [
            "The Finsen Centre, Rigshospitalet, Copenhagen, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lassen", 
        "givenName": "U", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Miami", 
          "id": "https://www.grid.ac/institutes/grid.26790.3a", 
          "name": [
            "University of Miami Miller School of Medicine, Miami, FL, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Merchan", 
        "givenName": "J", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute Curie", 
          "id": "https://www.grid.ac/institutes/grid.418596.7", 
          "name": [
            "Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.", 
            "INSERM U900 Research Unit, Saint-Cloud, France.", 
            "Paris-Saclay University, Paris, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Tourneau", 
        "givenName": "C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Paris-Sud", 
          "id": "https://www.grid.ac/institutes/grid.5842.b", 
          "name": [
            "Drug Development Department (DITEP), Institut Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800, Villejuif Cedex, France.", 
            "University Paris-Sud, Orsay, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soria", 
        "givenName": "J-C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Drug Development Department (DITEP), Institut Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800, Villejuif Cedex, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferte", 
        "givenName": "C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute Curie", 
          "id": "https://www.grid.ac/institutes/grid.418596.7", 
          "name": [
            "Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ricci", 
        "givenName": "F", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Diener", 
        "givenName": "J T", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuen", 
        "givenName": "E", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oakley", 
        "givenName": "G J", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Benhadji", 
        "givenName": "K A", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Drug Development Department (DITEP), Institut Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800, Villejuif Cedex, France. christophe.massard@gustaveroussy.fr."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Massard", 
        "givenName": "Christophe", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrc1186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004707046", 
          "https://doi.org/10.1038/nrc1186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004707046", 
          "https://doi.org/10.1038/nrc1186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004707046", 
          "https://doi.org/10.1038/nrc1186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.2321", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011781407"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.anndiagpath.2013.10.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014568449"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4103/0976-237x.96838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017995844"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4103/0976-237x.96838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017995844"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2011.278", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018966328", 
          "https://doi.org/10.1038/bjc.2011.278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1084/jem.20111855", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022641723"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.2643", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024397353", 
          "https://doi.org/10.1038/ng.2643"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08878", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026135489", 
          "https://doi.org/10.1038/nature08878"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08878", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026135489", 
          "https://doi.org/10.1038/nature08878"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(10)70245-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030426630"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci67201", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044831298"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(99)00229-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049505783"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci69070", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053073939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.67.5264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053962212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.284.5415.770", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062565091"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1538-7445.am2016-1133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063265624"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.1.5.159", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072292153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.30.5_suppl.299", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083399274"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1242/jcs.198119", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083841768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.20879", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091794571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105887442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2018.08.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106949957"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-06", 
    "datePublishedReg": "2019-04-06", 
    "description": "Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients with adenoid cystic carcinoma (ACC) who received the dose-escalation-recommended phase 2 dose (RP2D), established previously (Massard C, et al., Annals Oncol 2018, 29:1911-17). Methods Patients with advanced or metastatic cancer, measurable disease, ECOG-PS \u22641, and baseline tumor tissue were enrolled. Primary objectives were to identify a safe RP2D, confirm this dose in expansion cohorts, and document anti-tumor activity. Secondary objectives included safety and progression-free survival (PFS). The ACC expansion cohort received the RP2D regimen of 50\u00a0mg crenigacestat thrice per week in a 28-day\u00a0cycle until disease progression or other discontinuation criteria were met. Results Twenty-two patients with ACC were enrolled in the expansion cohort (median age of 60\u00a0years). Median treatment duration was 3\u00a0cycles with 6 patients remaining on treatment. There were no objective responses; 1 (5%) patient had an unconfirmed partial response. Disease control rate was 73% and 4 patients had stable disease \u22656\u00a0months. Median PFS was 5.3\u00a0months (95%CI: 2.4-NE)) for the 22 patients; and 7.7\u00a0months (95%CI: 4.0-NR) and 2.4\u00a0months (95%CI: 1.1-NE) in the subgroup of patients in second-line (n\u00a0=\u20097) or\u2009\u2265\u2009third-line (n\u00a0=\u20099), respectively. Frequent treatment-related-adverse events (all grades) included diarrhea, fatigue, vomiting, decreased appetite, dry mouth, and dry skin. There were no new safety signals. Conclusion The crenigacestat RP2D regimen induced manageable toxicity and limited clinical activity, without confirmed responses, in heavily pretreated patients with ACC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-019-00739-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }
    ], 
    "name": "Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.", 
    "productId": [
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30953269"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-019-00739-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113261863"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-019-00739-x", 
      "https://app.dimensions.ai/details/publication/pub.1113261863"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000372_0000000372/records_117087_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s10637-019-00739-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-019-00739-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-019-00739-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-019-00739-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-019-00739-x'


 

This table displays all metadata directly associated to this object as RDF triples.

220 TRIPLES      20 PREDICATES      46 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-019-00739-x schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nd1086a073d7544d7a6ee0ebd3678e271
4 schema:citation sg:pub.10.1038/bjc.2011.278
5 sg:pub.10.1038/nature08878
6 sg:pub.10.1038/ng.2643
7 sg:pub.10.1038/nrc1186
8 https://doi.org/10.1016/j.anndiagpath.2013.10.001
9 https://doi.org/10.1016/j.ejca.2008.10.026
10 https://doi.org/10.1016/j.ejca.2018.08.012
11 https://doi.org/10.1016/s0959-8049(99)00229-4
12 https://doi.org/10.1016/s1470-2045(10)70245-x
13 https://doi.org/10.1084/jem.20111855
14 https://doi.org/10.1093/annonc/mdy244
15 https://doi.org/10.1126/science.284.5415.770
16 https://doi.org/10.1158/1538-7445.am2016-1133
17 https://doi.org/10.1172/jci67201
18 https://doi.org/10.1172/jci69070
19 https://doi.org/10.1200/jco.2012.30.5_suppl.299
20 https://doi.org/10.1200/jco.2016.67.5264
21 https://doi.org/10.1242/jcs.198119
22 https://doi.org/10.18632/oncotarget.20879
23 https://doi.org/10.18632/oncotarget.2321
24 https://doi.org/10.4103/0976-237x.96838
25 https://doi.org/10.4161/cbt.1.5.159
26 schema:datePublished 2019-04-06
27 schema:datePublishedReg 2019-04-06
28 schema:description Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients with adenoid cystic carcinoma (ACC) who received the dose-escalation-recommended phase 2 dose (RP2D), established previously (Massard C, et al., Annals Oncol 2018, 29:1911-17). Methods Patients with advanced or metastatic cancer, measurable disease, ECOG-PS ≤1, and baseline tumor tissue were enrolled. Primary objectives were to identify a safe RP2D, confirm this dose in expansion cohorts, and document anti-tumor activity. Secondary objectives included safety and progression-free survival (PFS). The ACC expansion cohort received the RP2D regimen of 50 mg crenigacestat thrice per week in a 28-day cycle until disease progression or other discontinuation criteria were met. Results Twenty-two patients with ACC were enrolled in the expansion cohort (median age of 60 years). Median treatment duration was 3 cycles with 6 patients remaining on treatment. There were no objective responses; 1 (5%) patient had an unconfirmed partial response. Disease control rate was 73% and 4 patients had stable disease ≥6 months. Median PFS was 5.3 months (95%CI: 2.4-NE)) for the 22 patients; and 7.7 months (95%CI: 4.0-NR) and 2.4 months (95%CI: 1.1-NE) in the subgroup of patients in second-line (n = 7) or ≥ third-line (n = 9), respectively. Frequent treatment-related-adverse events (all grades) included diarrhea, fatigue, vomiting, decreased appetite, dry mouth, and dry skin. There were no new safety signals. Conclusion The crenigacestat RP2D regimen induced manageable toxicity and limited clinical activity, without confirmed responses, in heavily pretreated patients with ACC.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf sg:journal.1094201
33 schema:name Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
34 schema:productId N13e93c082d224d86a6651791588c406a
35 N440f3fa2e61343d9829aacc5bfd459c3
36 N55fa64b7196a40c5801a38c3dff2f702
37 Nf7af55a2cb3c45ffb766bc108e5f4131
38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113261863
39 https://doi.org/10.1007/s10637-019-00739-x
40 schema:sdDatePublished 2019-04-11T14:16
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N5f288454ab404a3492451db6d00615d9
43 schema:url http://link.springer.com/10.1007/s10637-019-00739-x
44 sgo:license sg:explorer/license/
45 sgo:sdDataset articles
46 rdf:type schema:ScholarlyArticle
47 N0de2f628b173409880433e018197b8ea schema:affiliation https://www.grid.ac/institutes/grid.26790.3a
48 schema:familyName Merchan
49 schema:givenName J
50 rdf:type schema:Person
51 N13e93c082d224d86a6651791588c406a schema:name doi
52 schema:value 10.1007/s10637-019-00739-x
53 rdf:type schema:PropertyValue
54 N1df53de06d1e45108f1b7480234c8b53 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
55 schema:familyName Diener
56 schema:givenName J T
57 rdf:type schema:Person
58 N398ee900defa47efadae8c16531742e6 rdf:first N1df53de06d1e45108f1b7480234c8b53
59 rdf:rest Ne16d2cd120a84bda875e4b706481c5bb
60 N3ca41f136b644be082b0c0b418f8e791 rdf:first N8a6407490f5e46ec8247ec1a67edfeb5
61 rdf:rest Nef4d26f4bb404c93b6abf6900df1b561
62 N440f3fa2e61343d9829aacc5bfd459c3 schema:name dimensions_id
63 schema:value pub.1113261863
64 rdf:type schema:PropertyValue
65 N48089f48ef07408cbfb9e5afbb08fdec schema:name Drug Development Department (DITEP), Institut Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800, Villejuif Cedex, France.
66 rdf:type schema:Organization
67 N55fa64b7196a40c5801a38c3dff2f702 schema:name pubmed_id
68 schema:value 30953269
69 rdf:type schema:PropertyValue
70 N58dbe0846e3d413ea4cca864f5ae1961 schema:name Drug Development Department (DITEP), Institut Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800, Villejuif Cedex, France.
71 rdf:type schema:Organization
72 N591b90b884594a18beaf7881b673af48 rdf:first N0de2f628b173409880433e018197b8ea
73 rdf:rest Na4d0c01036ae4af0a1a505cc51b847b5
74 N5cbafd8a526f4719bcca432a24ef9a4c schema:affiliation https://www.grid.ac/institutes/grid.417540.3
75 schema:familyName Benhadji
76 schema:givenName K A
77 rdf:type schema:Person
78 N5f288454ab404a3492451db6d00615d9 schema:name Springer Nature - SN SciGraph project
79 rdf:type schema:Organization
80 N7616823d283c4cee9dde90de43a916e1 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
81 schema:familyName Smith
82 schema:givenName C
83 rdf:type schema:Person
84 N8a6407490f5e46ec8247ec1a67edfeb5 schema:affiliation N58dbe0846e3d413ea4cca864f5ae1961
85 schema:familyName Ferte
86 schema:givenName C
87 rdf:type schema:Person
88 N8e35c15b0ce645f5b3e43e8b24e39a2d schema:affiliation https://www.grid.ac/institutes/grid.417540.3
89 schema:familyName Oakley
90 schema:givenName G J
91 rdf:type schema:Person
92 Na2385ab200a04ac6a679eb664cdf97da schema:affiliation https://www.grid.ac/institutes/grid.475435.4
93 schema:familyName Lassen
94 schema:givenName U
95 rdf:type schema:Person
96 Na4d0c01036ae4af0a1a505cc51b847b5 rdf:first Nef0a4328f79c4b38a71e8bb6176ffc12
97 rdf:rest Nd4a8c301678f4efe870b0ceb11236028
98 Na6bb64fa2da74348bf5947fda009fcef rdf:first N8e35c15b0ce645f5b3e43e8b24e39a2d
99 rdf:rest Nd50cc8d70dd34ae6a4cd6e31a8fc195c
100 Nbc8982a2874a44d9a0f1e343700426a1 schema:affiliation https://www.grid.ac/institutes/grid.5842.b
101 schema:familyName Soria
102 schema:givenName J-C
103 rdf:type schema:Person
104 Nbf8e0f0466da49f4bdc8df260a4ffb1a rdf:first Na2385ab200a04ac6a679eb664cdf97da
105 rdf:rest N591b90b884594a18beaf7881b673af48
106 Nc94563e2d4664687b54cd3f59a3c8718 schema:affiliation N48089f48ef07408cbfb9e5afbb08fdec
107 schema:familyName Even
108 schema:givenName C
109 rdf:type schema:Person
110 Nd041c4e2c049400780eacc0326f2d831 schema:name Drug Development Department (DITEP), Institut Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800, Villejuif Cedex, France. christophe.massard@gustaveroussy.fr.
111 rdf:type schema:Organization
112 Nd1086a073d7544d7a6ee0ebd3678e271 rdf:first Nc94563e2d4664687b54cd3f59a3c8718
113 rdf:rest Nbf8e0f0466da49f4bdc8df260a4ffb1a
114 Nd4a8c301678f4efe870b0ceb11236028 rdf:first Nbc8982a2874a44d9a0f1e343700426a1
115 rdf:rest N3ca41f136b644be082b0c0b418f8e791
116 Nd50cc8d70dd34ae6a4cd6e31a8fc195c rdf:first N5cbafd8a526f4719bcca432a24ef9a4c
117 rdf:rest Ned5c01d64e6e4bac993bc48eb878b202
118 Nda4ef55e0a0f4621b3585575d6a77e89 rdf:first N7616823d283c4cee9dde90de43a916e1
119 rdf:rest Na6bb64fa2da74348bf5947fda009fcef
120 Ndfbd14728f1045c6896191e3d00a55de schema:affiliation Nd041c4e2c049400780eacc0326f2d831
121 schema:familyName Massard
122 schema:givenName Christophe
123 rdf:type schema:Person
124 Ne16d2cd120a84bda875e4b706481c5bb rdf:first Ne68cc957fa7b4a09898b29323fba70c2
125 rdf:rest Nda4ef55e0a0f4621b3585575d6a77e89
126 Ne68cc957fa7b4a09898b29323fba70c2 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
127 schema:familyName Yuen
128 schema:givenName E
129 rdf:type schema:Person
130 Ned5c01d64e6e4bac993bc48eb878b202 rdf:first Ndfbd14728f1045c6896191e3d00a55de
131 rdf:rest rdf:nil
132 Nef0a4328f79c4b38a71e8bb6176ffc12 schema:affiliation https://www.grid.ac/institutes/grid.418596.7
133 schema:familyName Le Tourneau
134 schema:givenName C
135 rdf:type schema:Person
136 Nef4d26f4bb404c93b6abf6900df1b561 rdf:first Nff37a5cee8994616a3dffaf5cd678d5c
137 rdf:rest N398ee900defa47efadae8c16531742e6
138 Nf7af55a2cb3c45ffb766bc108e5f4131 schema:name nlm_unique_id
139 schema:value 8309330
140 rdf:type schema:PropertyValue
141 Nff37a5cee8994616a3dffaf5cd678d5c schema:affiliation https://www.grid.ac/institutes/grid.418596.7
142 schema:familyName Ricci
143 schema:givenName F
144 rdf:type schema:Person
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
149 schema:name Oncology and Carcinogenesis
150 rdf:type schema:DefinedTerm
151 sg:journal.1094201 schema:issn 0167-6997
152 1573-0646
153 schema:name Investigational New Drugs
154 rdf:type schema:Periodical
155 sg:pub.10.1038/bjc.2011.278 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018966328
156 https://doi.org/10.1038/bjc.2011.278
157 rdf:type schema:CreativeWork
158 sg:pub.10.1038/nature08878 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026135489
159 https://doi.org/10.1038/nature08878
160 rdf:type schema:CreativeWork
161 sg:pub.10.1038/ng.2643 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024397353
162 https://doi.org/10.1038/ng.2643
163 rdf:type schema:CreativeWork
164 sg:pub.10.1038/nrc1186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004707046
165 https://doi.org/10.1038/nrc1186
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1016/j.anndiagpath.2013.10.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014568449
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1016/j.ejca.2018.08.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106949957
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1016/s0959-8049(99)00229-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049505783
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1016/s1470-2045(10)70245-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1030426630
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1084/jem.20111855 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022641723
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1093/annonc/mdy244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105887442
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1126/science.284.5415.770 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062565091
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1158/1538-7445.am2016-1133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063265624
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1172/jci67201 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044831298
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1172/jci69070 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053073939
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1200/jco.2012.30.5_suppl.299 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083399274
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1200/jco.2016.67.5264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053962212
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1242/jcs.198119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083841768
194 rdf:type schema:CreativeWork
195 https://doi.org/10.18632/oncotarget.20879 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091794571
196 rdf:type schema:CreativeWork
197 https://doi.org/10.18632/oncotarget.2321 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011781407
198 rdf:type schema:CreativeWork
199 https://doi.org/10.4103/0976-237x.96838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017995844
200 rdf:type schema:CreativeWork
201 https://doi.org/10.4161/cbt.1.5.159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072292153
202 rdf:type schema:CreativeWork
203 https://www.grid.ac/institutes/grid.26790.3a schema:alternateName University of Miami
204 schema:name University of Miami Miller School of Medicine, Miami, FL, USA.
205 rdf:type schema:Organization
206 https://www.grid.ac/institutes/grid.417540.3 schema:alternateName Eli Lilly (United States)
207 schema:name Eli Lilly and Company, Indianapolis, IN, USA.
208 rdf:type schema:Organization
209 https://www.grid.ac/institutes/grid.418596.7 schema:alternateName Institute Curie
210 schema:name Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
211 INSERM U900 Research Unit, Saint-Cloud, France.
212 Paris-Saclay University, Paris, France.
213 rdf:type schema:Organization
214 https://www.grid.ac/institutes/grid.475435.4 schema:alternateName Rigshospitalet
215 schema:name The Finsen Centre, Rigshospitalet, Copenhagen, Denmark.
216 rdf:type schema:Organization
217 https://www.grid.ac/institutes/grid.5842.b schema:alternateName University of Paris-Sud
218 schema:name Drug Development Department (DITEP), Institut Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800, Villejuif Cedex, France.
219 University Paris-Sud, Orsay, France.
220 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...